IN2014DN07149A - - Google Patents

Info

Publication number
IN2014DN07149A
IN2014DN07149A IN7149DEN2014A IN2014DN07149A IN 2014DN07149 A IN2014DN07149 A IN 2014DN07149A IN 7149DEN2014 A IN7149DEN2014 A IN 7149DEN2014A IN 2014DN07149 A IN2014DN07149 A IN 2014DN07149A
Authority
IN
India
Prior art keywords
antibodies
diagnosis
treatment
present application
application discloses
Prior art date
Application number
Other languages
English (en)
Inventor
Jose Saldanha
Tarlochan S Nijjar
Original Assignee
Neotope Biosciences Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neotope Biosciences Ltd filed Critical Neotope Biosciences Ltd
Publication of IN2014DN07149A publication Critical patent/IN2014DN07149A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/001—Preparation for luminescence or biological staining
    • A61K49/0013—Luminescence
    • A61K49/0017—Fluorescence in vivo
    • A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
    • A61K49/0058—Antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/08—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by the carrier
    • A61K49/10—Organic compounds
    • A61K49/14—Peptides, e.g. proteins
    • A61K49/16—Antibodies; Immunoglobulins; Fragments thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
    • A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/567—Framework region [FR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/71—Decreased effector function due to an Fc-modification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
IN7149DEN2014 2012-01-27 2013-01-25 IN2014DN07149A (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261591835P 2012-01-27 2012-01-27
US201261711207P 2012-10-08 2012-10-08
PCT/US2013/023307 WO2013112945A1 (en) 2012-01-27 2013-01-25 Humanized antibodies that recognize alpha-synuclein

Publications (1)

Publication Number Publication Date
IN2014DN07149A true IN2014DN07149A (de) 2015-04-24

Family

ID=48873980

Family Applications (1)

Application Number Title Priority Date Filing Date
IN7149DEN2014 IN2014DN07149A (de) 2012-01-27 2013-01-25

Country Status (23)

Country Link
US (7) US8790644B2 (de)
EP (1) EP2807188B1 (de)
JP (2) JP6342333B2 (de)
KR (2) KR102086061B1 (de)
CN (2) CN104619724B (de)
AU (1) AU2013211874B2 (de)
BR (1) BR112014018561A8 (de)
CA (1) CA2863953A1 (de)
CL (1) CL2014001984A1 (de)
DK (1) DK2807188T3 (de)
ES (1) ES2749457T3 (de)
HK (1) HK1204791A1 (de)
IL (2) IL233829B (de)
IN (1) IN2014DN07149A (de)
MX (2) MX360778B (de)
MY (1) MY171140A (de)
NZ (1) NZ629296A (de)
PH (1) PH12014501685A1 (de)
RU (1) RU2642262C2 (de)
SG (1) SG11201404321YA (de)
UA (1) UA115439C2 (de)
WO (1) WO2013112945A1 (de)
ZA (1) ZA201406227B (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2771031B1 (de) 2011-10-28 2018-04-18 Prothena Biosciences Limited Alpha-synuklein erkennende humanisierte antikörper
NZ629296A (en) 2012-01-27 2016-06-24 Prothena Biosciences Ltd Humanized antibodies that recognize alpha-synuclein
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US10465006B2 (en) * 2013-07-05 2019-11-05 Genmab A/S Humanized or chimeric CD3 antibodies
AU2014351996B2 (en) * 2013-11-21 2020-01-02 F. Hoffmann-La Roche Ag Anti-alpha-synuclein antibodies and methods of use
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
WO2016061389A2 (en) 2014-10-16 2016-04-21 Genentech, Inc. Anti-alpha-synuclein antibodies and methods of use
CN106568969B (zh) * 2016-10-19 2017-09-26 首都医科大学 一种丝氨酸129位磷酸化alpha‑突触核蛋白聚集体的ELISA检测方法
EP3548074A4 (de) 2016-12-02 2020-07-01 Prothena Biosciences Limited Infrarottest zur detektion von sekundären strukturprofilen von alpha-synuklein
EP3583124A1 (de) * 2017-02-17 2019-12-25 Bristol-Myers Squibb Company Antikörper gegen alpha-synuklein und verwendungen davon
EP3406632A1 (de) 2017-05-23 2018-11-28 S.I.S.S.A. Scuola Internazionale Superiore di Studi Avanzati An prionprotein bindende liganden zur verwendung bei der behandlung von synukleinopathien
EP3725806A4 (de) * 2017-12-14 2022-03-30 ABL Bio Inc. Bispezifischer antikörper gegen a-syn/igf1r und seine verwendung
GB201720975D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Anti-alpha synuclein antibodies
GB201720970D0 (en) 2017-12-15 2018-01-31 Ucb Biopharma Sprl Antibodies
AU2019247511A1 (en) 2018-04-06 2020-10-22 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
CN112839710A (zh) 2018-08-09 2021-05-25 霍夫曼-拉罗奇有限公司 帕金森氏病的确定
CA3111907A1 (en) * 2018-10-19 2020-04-23 Janssen Vaccines & Prevention B.V. Anti-synuclein antibodies
AU2020358854A1 (en) 2019-10-03 2022-05-26 Atyr Pharma, Inc. Compositions and methods comprising anti-NRP2 antibodies
MX2022013173A (es) 2020-04-24 2022-11-30 Hoffmann La Roche Modulacion de enzimas y vias con compuestos de sulfhidrilo y sus derivados.
MX2023000949A (es) * 2020-07-23 2023-02-22 Othair Prothena Ltd Anticuerpos anti-beta-amiloide (abeta).
CN113912714B (zh) * 2021-12-15 2022-02-22 北京凯祥弘康生物科技有限公司 特异性结合α-突触核蛋白的抗体及其应用

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
EP0307434B2 (de) 1987-03-18 1998-07-29 Scotgen Biopharmaceuticals, Inc. Geänderte antikörper
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
IE64738B1 (en) 1990-03-20 1995-09-06 Akzo Nv Stabilized gonadotropin containing preparations
ES2206447T3 (es) 1991-06-14 2004-05-16 Genentech, Inc. Anticuerpo humanizado para heregulina.
US5786464C1 (en) 1994-09-19 2012-04-24 Gen Hospital Corp Overexpression of mammalian and viral proteins
JP2000510813A (ja) 1995-02-06 2000-08-22 ジェネテイックス・インスティテュート・インコーポレイテッド Ｉｌ−１２用処方
DE19539493A1 (de) 1995-10-24 1997-04-30 Thomae Gmbh Dr K Starker homologer Promotor aus Hamster
US5834597A (en) 1996-05-20 1998-11-10 Protein Design Labs, Inc. Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same
US6114148C1 (en) 1996-09-20 2012-05-01 Gen Hospital Corp High level expression of proteins
US5888809A (en) 1997-05-01 1999-03-30 Icos Corporation Hamster EF-1α transcriptional regulatory DNA
CN100405399C (zh) 1999-02-05 2008-07-23 三星电子株式会社 图像纹理恢复方法及其装置
WO2004006955A1 (en) 2001-07-12 2004-01-22 Jefferson Foote Super humanized antibodies
WO2004039234A2 (en) 2002-05-13 2004-05-13 Alexion Pharmaceuticals, Inc. Humanized antibodies against the venezuelan equine encephalitis virus
US8506959B2 (en) 2002-11-01 2013-08-13 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
TW200509968A (en) 2002-11-01 2005-03-16 Elan Pharm Inc Prevention and treatment of synucleinopathic disease
WO2008103472A2 (en) * 2007-02-23 2008-08-28 Elan Pharmaceuticals, Inc. Prevention and treatment of synucleinopathic and amyloidogenic disease
US9034337B2 (en) * 2003-10-31 2015-05-19 Prothena Biosciences Limited Treatment and delay of outset of synucleinopathic and amyloidogenic disease
US20080014194A1 (en) 2003-10-31 2008-01-17 Elan Pharmaceuticals, Inc. Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease
CA2507664C (en) 2002-11-29 2010-09-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Novel neomycin-phosphotransferase-genes and methods for the selection of recombinant cells producing high levels of a desired gene product
BRPI0403964B8 (pt) 2003-04-04 2021-05-25 Genentech Inc formulações líquidas estáveis, artigo manufaturado e uso dessas formulações para o tratamento de disfunção mediada por ige
US7358331B2 (en) 2003-05-19 2008-04-15 Elan Pharmaceuticals, Inc. Truncated fragments of alpha-synuclein in Lewy body disease
DE10338531A1 (de) 2003-08-19 2005-04-07 Boehringer Ingelheim Pharma Gmbh & Co. Kg Verfahren zur Reklonierung von Produktionszellen
WO2005047860A2 (en) 2003-11-08 2005-05-26 Elan Pharmaceuticals, Inc. Antibodies to alpha-synuclein
EP2221315A1 (de) 2003-12-04 2010-08-25 Xencor, Inc. Verfahren zur Erzeugung von Proteinvarianten mit erhöhtem Wirtsstranginhalt und Zusammensetzungen davon
JO3000B1 (ar) 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
DK1820022T3 (da) 2004-11-10 2009-09-14 Boehringer Ingelheim Pharma Anvendelse af flow-cytometrisk analyse for at optimere cellebanks-strategier af CHO-celler
US7930064B2 (en) * 2004-11-19 2011-04-19 Parata Systems, Llc Automated drug discrimination during dispensing
US20080300204A1 (en) 2005-07-19 2008-12-04 University Of Rochester Alpha-Synuclein Antibodies and Methods Related Thereto
KR101605207B1 (ko) 2006-07-14 2016-03-22 에이씨 이뮨 에스.에이. 아밀로이드 베타에 대해 인간화된 항체
US20080124760A1 (en) 2006-07-26 2008-05-29 Barbara Enenkel Regulatory Nucleic Acid Elements
CN103408661B (zh) * 2007-01-05 2016-04-06 苏黎世大学 提供疾患特异性结合分子和靶的方法
US8147833B2 (en) 2007-02-23 2012-04-03 Neotope Biosciences Limited Prevention and treatment of synucleinopathic and amyloidogenic disease
US20100111966A1 (en) 2007-02-23 2010-05-06 Schering Corporation Engineered anti-il-23p19 antibodies
MY148472A (en) 2007-03-02 2013-04-30 Boehringer Ingelheim Pharma Improvement of protein production
SI2132230T1 (sl) 2007-03-22 2014-07-31 Genentech, Inc. Apoptotska protitelesa, ki veĹľejo membransko-vezan IgE
BRPI0809112A2 (pt) 2007-03-22 2014-08-26 Imclone Llc Formulações estáveis de anticorpos
EP2031064A1 (de) 2007-08-29 2009-03-04 Boehringer Ingelheim Pharma GmbH & Co. KG Verfahren zur Steigerung von Proteintitern
KR101247418B1 (ko) 2007-12-21 2013-03-25 에프. 호프만-라 로슈 아게 항체 제형
ES2544679T3 (es) 2007-12-28 2015-09-02 Prothena Biosciences Limited Tratamiento y profilaxis de la amiloidosis
AT506535B1 (de) * 2008-02-22 2010-04-15 Affiris Forschungs & Entwicklungs Gmbh Vaccine enthaltend alpha-synuclein-mimotope auf basis von peptiden
EP2282758B1 (de) 2008-04-29 2018-11-21 BioArctic AB Antikörper und vakzine zur verwendung bei therapeutischen und diagnostischen verfahren für alpha-synuclein-vermittelte erkrankungen
WO2009141239A1 (en) 2008-05-20 2009-11-26 F. Hoffmann-La Roche Ag A pharmaceutical formulation comprising an antibody against ox40l, uses thereof
US20120276019A1 (en) 2008-07-25 2012-11-01 Diamedica Inc. Tissue kallikrein for the treatment of parkinson's disease
DE102008048129A1 (de) 2008-09-20 2010-04-22 Lfk-Lenkflugkörpersysteme Gmbh Flugkörper mit zumindest einem Bremsfallschirm sowie Befestigungsvorrichtung zur Befestigung eines Bremsfallschirms an einem Flugkörper
SI2949666T1 (sl) 2008-12-19 2019-03-29 Biogen International Neuroscience Gmbh Človeška anti alfa-sinukleinska protitelesa
RU2733466C2 (ru) 2009-07-28 2020-10-01 Шайр Хьюман Дженетик Терапиз Композиции и способы для лечения болезни гоше
AR078161A1 (es) 2009-09-11 2011-10-19 Hoffmann La Roche Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
EP2519537A4 (de) 2009-12-29 2013-07-10 Reddys Lab Ltd Dr Reinigung von proteinen
EP2366714A1 (de) 2010-03-03 2011-09-21 Dr. Rentschler Holding GmbH & Co. KG Natürlich auftretende Autoantikörper gegen Alpha-Synuklein, die die Aggregation und Zytotoxizität von Alpha-Synuklein inhibieren
TW201134488A (en) 2010-03-11 2011-10-16 Ucb Pharma Sa PD-1 antibodies
EP2560994B1 (de) * 2010-04-08 2016-10-12 JN Biosciences LLC Antikörper gegen cd122
CA3220104A1 (en) * 2010-06-08 2011-12-15 Genentech, Inc. Cysteine engineered antibodies and conjugates
TR201807750T4 (tr) * 2010-06-11 2018-06-21 Kyowa Hakko Kirin Co Ltd Anti-TIM-3 antikoru.
LT2593128T (lt) * 2010-07-15 2018-06-25 Adheron Therapeutics, Inc. Humanizuoti antikūnai, nukreipti į kadherino-11 ec1 domeną, ir susijusios kompozicijos ir būdai
KR20130142128A (ko) 2010-10-11 2013-12-27 애브비 인코포레이티드 단백질의 정제 방법
US8741298B2 (en) 2011-02-07 2014-06-03 Neotope Biosciences Limited APOE immunotherapy
WO2012160536A1 (en) 2011-05-26 2012-11-29 Dr Reddy's Laboratories Limited Antibody purification
CA2840224C (en) 2011-06-22 2019-08-13 The General Hospital Corporation Treatment of proteinopathies
WO2013003680A1 (en) 2011-06-30 2013-01-03 Genentech, Inc. Anti-c-met antibody formulations
EP2771031B1 (de) 2011-10-28 2018-04-18 Prothena Biosciences Limited Alpha-synuklein erkennende humanisierte antikörper
MX363226B (es) 2011-10-31 2019-03-15 Genentech Inc Formulaciones de anticuerpos.
NZ629296A (en) 2012-01-27 2016-06-24 Prothena Biosciences Ltd Humanized antibodies that recognize alpha-synuclein
CN104520329A (zh) 2012-08-29 2015-04-15 霍夫曼-拉罗奇有限公司 血脑屏障穿梭体
UA118441C2 (uk) 2012-10-08 2019-01-25 Протена Біосаєнсиз Лімітед Антитіло, що розпізнає альфа-синуклеїн
US10513555B2 (en) 2013-07-04 2019-12-24 Prothena Biosciences Limited Antibody formulations and methods
US10562973B2 (en) 2014-04-08 2020-02-18 Prothena Bioscience Limited Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein
US10084674B2 (en) 2015-09-09 2018-09-25 International Business Machines Corporation Virtual desktop operation and data continuity preservation

Also Published As

Publication number Publication date
US20150024433A1 (en) 2015-01-22
AU2013211874B2 (en) 2017-11-02
US20130266517A1 (en) 2013-10-10
US20160251416A1 (en) 2016-09-01
RU2642262C2 (ru) 2018-01-24
MY171140A (en) 2019-09-27
WO2013112945A1 (en) 2013-08-01
PH12014501685A1 (en) 2014-11-10
KR20140125409A (ko) 2014-10-28
IL233829B (en) 2021-04-29
US9234031B2 (en) 2016-01-12
MX2018014044A (es) 2021-12-08
JP2018148911A (ja) 2018-09-27
UA115439C2 (uk) 2017-11-10
HK1204791A1 (en) 2015-12-04
KR102086061B1 (ko) 2020-03-11
US10597441B2 (en) 2020-03-24
US10118960B2 (en) 2018-11-06
NZ629296A (en) 2016-06-24
BR112014018561A8 (pt) 2017-07-11
EP2807188A1 (de) 2014-12-03
ZA201406227B (en) 2016-02-24
CN104619724A (zh) 2015-05-13
US20190153080A1 (en) 2019-05-23
US20180016329A1 (en) 2018-01-18
AU2013211874A1 (en) 2014-09-18
SG11201404321YA (en) 2014-08-28
ES2749457T3 (es) 2020-03-20
US8790644B2 (en) 2014-07-29
DK2807188T3 (da) 2019-10-07
BR112014018561A2 (de) 2017-06-20
MX360778B (es) 2018-11-16
US20150056187A1 (en) 2015-02-26
CA2863953A1 (en) 2013-08-01
MX2014008952A (es) 2015-02-20
IL281731A (en) 2021-05-31
RU2014134747A (ru) 2016-03-20
JP6807893B2 (ja) 2021-01-06
US20200277362A1 (en) 2020-09-03
JP6342333B2 (ja) 2018-06-13
EP2807188A4 (de) 2015-07-01
US10875909B2 (en) 2020-12-29
US9217030B2 (en) 2015-12-22
KR102246217B1 (ko) 2021-04-29
CN108517010A (zh) 2018-09-11
KR20200027570A (ko) 2020-03-12
EP2807188B1 (de) 2019-09-11
JP2015508062A (ja) 2015-03-16
US9670273B2 (en) 2017-06-06
CL2014001984A1 (es) 2014-12-19
CN104619724B (zh) 2018-05-04
IL233829A0 (en) 2014-09-30

Similar Documents

Publication Publication Date Title
IN2014DN07149A (de)
MX2019014658A (es) Anticuerpos humanizados que reconocen la alfa-sinucleina.
GEP20217263B (en) Anti-cd27 antibodies
MX2016003129A (es) Terapia de combinacion de anticuerpos contra el csf-1r humano y anticuerpos contralel pd-l1 humano.
EA201591198A1 (ru) Антитела к gdf15
PH12015500114B1 (en) HUMAN ANTIBODIES TO GFRa3 AND METHODS OF USE THEREOF
EA201791186A1 (ru) Антитела к cd38
UA107827C2 (en) Antibody cd40
EA201491541A1 (ru) АНТИТЕЛА ПРОТИВ ИНТЕГРИНОВ αvβ6 И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ЗЛОКАЧЕСТВЕННЫХ НОВООБРАЗОВАНИЙ
EP2955195A4 (de) Anti-semaphorin-3a-antikörper und behandlung von alzheimer und entzündlichen immunerkrankungen damit
EP3010938A4 (de) Fcrn-spezifischer menschlicher antikörper und zusammensetzung zur behandlung von autoimmunkrankheiten
MY164579A (en) Safe and functional humanized antibodies
MX2015011772A (es) Anticuerpos anti-hepcidina y usos de los mismos.
HK1258028A1 (zh) 人類抗體及其在神經疾病治療中的診斷和治療用途
EP2694530A4 (de) Neue peptide zur bindung an einzelne typen der mhc-klasse-ii und ihre verwendung bei diagnose und behandlung
EP2700652A4 (de) Diagnose und behandlung von krebs mittels anti-itm2a-antikörpern
EP3628326C0 (de) Verfahren und materialien zur behandlung von morbus pompe
GB201109238D0 (en) Antibodies
HK1201045A1 (en) Compositions and methods for the diagnosis and treatment of tumor
EP2563395A4 (de) Schmerzbehandlung von unter augenerkrankungen leidenden patienten mit antikörpern gegen s1p
FR2979346B1 (fr) Nanocorps anti-vcam-1
EP2569334A4 (de) Rekombinant hergestellte antikörper zur anzielung von erbb-signalisierungsmolekülen sowie verfahren zu ihrer verwendung zur krankheitsdiagnose und -behandlung
IL284807A (en) Antibodies specific for human nectin-2
MX2013009529A (es) Tratamiento de enfermedad de crohn con fistulas.
LT2984108T (lt) Anti-s100a7 antikūnai, skirti vėžio gydymui ir diagnozei